CORT
Neutral signalScored 2026-10-25 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Corcept Therapeutics Incorporated
- Nom
- Corcept Therapeutics Incorporated
- Secteur
- Healthcare
- Industrie
- Medical - Pharmaceuticals
- Bourse
- NASDAQ
- Capitalisation
- $9.4B
- Employés
- 730
- PDG
- Joseph K. Belanoff
- Site web
- https://www.corcept.com
- Marché
- MBXSPRB
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 26 685 titres (~3 270 169,36 $ US)
- Insiders
- Park Kimberly
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$11,133,808
Avg sell (VWAP, 90d window) $117.93 vs last close $87.13 (-26.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$7,687,832 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-26
- Liquidity
- Liquid $77,406,118/day · 20d vol
- Last synced
-
2026-10-26 21:10:17
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-02 | Lyon Joseph Douglas | Sell · S · 10b5-1 | 4,744 | $116.54 | $552,869 | Form 4 |
| 2026-10-02 | Maduck Sean | Sell · S · 10b5-1 | 8,744 | $116.55 | $1,019,143 | Form 4 |
| 2026-10-02 | Vieira Roberto Wandenkolk | Sell · S · 10b5-1 | 5,147 | $116.58 | $600,063 | Form 4 |
| 2026-10-01 | Lyon Joseph Douglas | Sell · S · 10b5-1 | 810 | $115.40 | $93,473 | Form 4 |
| 2026-10-01 | Maduck Sean | Sell · S · 10b5-1 | 413 | $115.54 | $47,717 | Form 4 |
| 2026-09-16 | Vieira Roberto Wandenkolk | Sell · S · 10b5-1 | 296 | $100.82 | $29,843 | Form 4 |
| 2026-09-14 | Lyon Joseph Douglas | Sell · S · 10b5-1 | 2,188 | $114.12 | $249,686 | Form 4 |
| 2026-09-02 | Vieira Roberto Wandenkolk | Sell · S · 10b5-1 | 1,225 | $115.44 | $141,413 | Form 4 |
| 2026-09-01 | Maduck Sean | Sell · S · 10b5-1 | 2,281 | $115.61 | $263,711 | Form 4 |
| 2026-08-26 | Park Kimberly | Sell · S | 26,685 | $122.55 | $3,270,169 | Form 4 |
| 2026-08-25 | Maduck Sean | Sell · S · 10b5-1 | 5,870 | $126.06 | $739,965 | Form 4 |
| 2026-08-14 | Maduck Sean | Sell · S · 10b5-1 | 3,664 | $114.49 | $419,491 | Form 4 |
| 2026-08-10 | Guyer William | Sell · S · 10b5-1 | 4,770 | $114.04 | $543,957 | Form 4 |
| 2026-08-10 | Maduck Sean | Sell · S · 10b5-1 | 1,031 | $114.52 | $118,068 | Form 4 |
| 2026-08-04 | Guyer William | Sell · S · 10b5-1 | 3,700 | $113.12 | $418,562 | Form 4 |
| 2026-08-03 | Lyon Joseph Douglas | Sell · S | 1,540 | $114.16 | $175,806 | Form 4 |
| 2026-08-03 | Maduck Sean | Sell · S · 10b5-1 | 20,305 | $114.70 | $2,329,075 | Form 4 |
| 2026-07-30 | Mokari Atabak | Sell · S · 10b5-1 | 1,001 | $120.67 | $120,796 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-25 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
CORT combines an extremely strong balance sheet (liquidity score 85) with a moderate catalyst (ADA/EASD consensus report expanding hypercortisolism screening in T2D), but the severe contraction in operating margins and…
The first sentence of the analysis written for CORT on 2026-10-25 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 2.92 · operating margin 5.9%
Suggested stop 79.25, nearest stored support minus 0.5 ATR(9.0% under the last close). Reward/risk to the next stored resistance is 1.01. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-20 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolo
- 2026-10-20 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published their consensus report on the Management of Type 2 Diabetes, 2026.
- 2026-10-19 Can Lifyorli Aid Corcept''s Long-Term Growth Prospects Beyond Korlym? CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.
- 2026-10-19 Corcept Therapeutics (NASDAQ:CORT) Director Sells $1,148,100.00 in Stock Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) Director James Wilson sold 10,000 shares of the company''s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $114.81, for a total value of $1,148,100.00. Following the completion of the sale, the director directly owned 1,054,543 shares of the
- 2026-10-18 Corcept Therapeutics Incorporated $CORT Stock Holdings Cut by First Citizens Bank & Trust Co. First Citizens Bank and Trust Co. trimmed its holdings in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 62.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,145 shares of the biotechnology company''s stock after selling 6,771 shares during the period. First Citizens
- 2026-10-16 Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.
- 2026-10-15 3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge As inflation surges on rising energy costs, CAH, UNH and CORT stand out as low-beta healthcare stocks with strong expected earnings growth and defensive appeal.
- 2026-10-13 Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Has Consensus Target Price of $138.17 According to Analysts Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating
- 2026-10-04 Analyzing Xeris Biopharma (NASDAQ:XERS) and Corcept Therapeutics (NASDAQ:CORT) Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Corcept Therapeutics (NASDAQ: CORT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Institutional and Insider Ownership 42.7% of Xeris Biopharma
- 2026-10-02 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | |
| Ebit Margin | 8.7% | 23.9% | 25.8% | 28.9% | 34.2% | |
| Ebitda Margin | 9.0% | 24.1% | 26.3% | 29.8% | 35.0% | |
| Operating Profit Margin | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | |
| Pretax Profit Margin | 8.7% | 23.9% | 25.8% | 28.9% | 34.2% | |
| Continuous Operations Profit Margin | 13.1% | 20.9% | 22.0% | 25.2% | 30.7% | |
| Net Profit Margin | 13.1% | 20.7% | 22.0% | 25.2% | 30.7% | |
| Bottom Line Profit Margin | 12.9% | 20.7% | 21.9% | 25.2% | 30.7% | |
| Current Ratio | 2.923 | 3.350 | 4.389 | 6.887 | 5.605 | |
| Quick Ratio | 2.846 | 3.262 | 4.315 | 6.803 | 5.500 | |
| Solvency Ratio | 0.538 | 0.876 | 0.945 | 1.285 | 2.410 | |
| Cash Ratio | 0.726 | 0.907 | 1.297 | 0.915 | 1.633 | |
| Price To Earnings Ratio | 36.632 | 37.326 | 31.843 | 21.379 | 20.412 | |
| Price To Earnings Growth Ratio | -1.236 | 1.154 | 4.322 | -10.369 | 3.756 | |
| Forward Price To Earnings Growth Ratio | -1.236 | 1.154 | 4.322 | -10.369 | 3.756 | |
| Price To Earnings Diluted Ratio | 42.439 | 40.967 | 34.553 | 23.345 | 22.247 | |
| Price To Earnings Diluted Growth Ratio | -1.273 | 1.328 | 4.294 | -10.388 | 4.728 | |
| Price To Book Ratio | 5.579 | 7.654 | 6.638 | 4.322 | 6.093 | |
| Price To Sales Ratio | 4.747 | 7.706 | 6.973 | 5.397 | 6.257 | |
| Price To Free Cash Flow Ratio | 25.492 | 26.554 | 26.506 | 18.087 | 13.678 | |
| Price To Operating Cash Flow Ratio | 25.454 | 26.263 | 26.477 | 18.025 | 13.639 | |
| Debt To Assets Ratio | 0.007 | 0.008 | 0.000 | 0.002 | 0.001 | |
| Debt To Equity Ratio | 0.009 | 0.010 | 0.000 | 0.002 | 0.001 | |
| Debt To Capital Ratio | 0.009 | 0.010 | 0.000 | 0.002 | 0.001 | |
| Long Term Debt To Capital Ratio | 0.008 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.292 | 1.237 | 1.227 | 1.163 | 1.128 | |
| Working Capital Turnover Ratio | 2.342 | 1.971 | 1.235 | 1.245 | 1.126 | |
| Operating Cash Flow Ratio | 0.855 | 1.407 | 1.216 | 1.660 | 3.532 | |
| Operating Cash Flow Sales Ratio | 0.186 | 0.293 | 0.263 | 0.299 | 0.459 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.999 | 0.989 | 0.999 | 0.997 | 0.997 | |
| Debt Service Coverage Ratio | 0.000 | 171.948 | 718.556 | 91.745 | 219.504 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 238.923 | 841.318 | 105.269 | 319.186 | |
| Operating Cash Flow Coverage Ratio | 23.251 | 28.556 | 841.318 | 105.269 | 319.186 | |
| Capital Expenditure Coverage Ratio | 672.967 | 91.191 | 913.950 | 291.339 | 357.979 | |
| Dividend Paid And Capex Coverage Ratio | 672.967 | 91.191 | 913.950 | 291.339 | 357.979 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 51.205 | 31.205 | 25.435 | 17.584 | 17.294 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 98.3% | ▼-0.1% | ▼-0.2% |
| Ebit Margin | 8.7% | ▼-15.2% | ▼-15.6% |
| Ebitda Margin | 9.0% | ▼-15.1% | ▼-15.8% |
| Operating Profit Margin | 5.9% | ▼-14.4% | ▼-16.2% |
| Pretax Profit Margin | 8.7% | ▼-15.2% | ▼-15.6% |
| Continuous Operations Profit Margin | 13.1% | ▼-7.8% | ▼-9.3% |
| Net Profit Margin | 13.1% | ▼-7.6% | ▼-9.3% |
| Bottom Line Profit Margin | 12.9% | ▼-7.8% | ▼-9.4% |
| Current Ratio | 2.923 | ▼-0.427 | ▼-1.708 |
| Quick Ratio | 2.845 | ▼-0.416 | ▼-1.700 |
| Solvency Ratio | 0.538 | ▼-0.339 | ▼-0.673 |
| Cash Ratio | 0.726 | ▼-0.181 | ▼-0.370 |
| Price To Earnings Ratio | 36.632 | ▼-0.694 | ▲7.113 |
| Price To Earnings Growth Ratio | -1.236 | ▼-2.390 | ▼-0.761 |
| Forward Price To Earnings Growth Ratio | -1.236 | ▼-2.390 | ▼-0.761 |
| Price To Earnings Diluted Ratio | 42.439 | ▲1.472 | ▲9.729 |
| Price To Earnings Diluted Growth Ratio | -1.273 | ▼-2.601 | ▼-1.011 |
| Price To Book Ratio | 5.580 | ▼-2.075 | ▼-0.478 |
| Price To Sales Ratio | 4.747 | ▼-2.959 | ▼-1.469 |
| Price To Free Cash Flow Ratio | 25.492 | ▼-1.062 | ▲3.429 |
| Price To Operating Cash Flow Ratio | 25.454 | ▼-0.809 | ▲3.482 |
| Debt To Assets Ratio | 0.007 | ▼-0.001 | ▲0.004 |
| Debt To Equity Ratio | 0.009 | ▼-0.001 | ▲0.005 |
| Debt To Capital Ratio | 0.009 | ▼-0.001 | ▲0.005 |
| Long Term Debt To Capital Ratio | 0.008 | ▲0.008 | ▲0.006 |
| Financial Leverage Ratio | 1.292 | ▲0.055 | ▲0.083 |
| Working Capital Turnover Ratio | 2.342 | ▲0.371 | ▲0.758 |
| Operating Cash Flow Ratio | 0.855 | ▼-0.552 | ▼-0.879 |
| Operating Cash Flow Sales Ratio | 0.186 | ▼-0.107 | ▼-0.114 |
| Free Cash Flow Operating Cash Flow Ratio | 0.999 | ▲0.009 | ▲0.003 |
| Debt Service Coverage Ratio | 0.000 | ▼-171.948 | ▼-240.351 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▼-238.923 | ▼-300.939 |
| Operating Cash Flow Coverage Ratio | 23.251 | ▼-5.305 | ▼-240.265 |
| Capital Expenditure Coverage Ratio | 672.967 | ▲581.776 | ▲207.482 |
| Dividend Paid And Capex Coverage Ratio | 672.967 | ▲581.776 | ▲207.482 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 51.205 | ▲20.000 | ▲22.660 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.61B | $5.20B | $3.36B | $2.17B | $2.29B | |
| Enterprise value | $3.50B | $5.08B | $3.23B | $2.10B | $2.21B | |
| EV / Sales | 4.60x | 7.53x | 6.69x | 5.24x | 6.05x | |
| EV / Op. cash flow | 24.65x | 25.65x | 25.41x | 17.48x | 13.18x | |
| EV / Free cash flow | 24.68x | 25.94x | 25.44x | 17.54x | 13.22x | |
| EV / EBITDA | 51.20x | 31.20x | 25.43x | 17.58x | 17.29x | |
| Net debt / EBITDA | -1.67x | -0.74x | -1.07x | -0.55x | -0.60x | |
| Current ratio | 2.92x | 3.35x | 4.39x | 6.89x | 5.61x | |
| Income quality | 1.45x | 1.40x | 1.20x | 1.19x | 1.49x | |
| Graham number | $12 | $14 | $11 | $10 | $8 | |
| Graham net-net | $2 | $3 | $3 | $4 | $2 | |
| Tax burden | 149.9% | 86.5% | 85.2% | 87.3% | 90.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $319.4M | $330.8M | $354.1M | $426.8M | $218.9M | |
| Invested capital | $325.9M | $338.8M | $354.4M | $428.5M | $220.4M | |
| Return on assets | 11.9% | 16.6% | 17.1% | 17.4% | 26.6% | |
| Operating ROA | 5.3% | 18.7% | 17.8% | 22.4% | 25.0% | |
| Return on tangible assets | 11.9% | 16.6% | 17.1% | 17.4% | 26.6% | |
| Return on equity | 15.4% | 20.6% | 20.9% | 20.2% | 29.9% | |
| Return on invested capital | 6.7% | 17.1% | 17.7% | 19.2% | 29.7% | |
| Return on capital employed | 6.7% | 19.6% | 20.8% | 22.0% | 33.1% | |
| Earnings yield | 2.8% | 2.7% | 3.2% | 4.7% | 4.9% | |
| Free cash flow yield | 3.9% | 3.8% | 3.8% | 5.5% | 7.3% | |
| Capex / Op. cash flow | 0.1% | 1.1% | 0.1% | 0.3% | 0.3% | |
| Capex / Depreciation | 11.2% | 162.6% | 5.9% | 12.0% | 15.3% | |
| Capex / Sales | 0.0% | 0.3% | 0.0% | 0.1% | 0.1% | |
| SG&A / Sales | 58.9% | 41.5% | 38.2% | 38.0% | 33.4% | |
| R&D / Sales | 33.5% | 36.6% | 38.2% | 32.6% | 31.1% | |
| Stock comp / Sales | 11.1% | 9.1% | 10.1% | 10.6% | 11.7% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 29d | 31d | 43d | 43d | 29d | |
| Days payables outstanding | 1138d | 516d | 980d | 812d | 477d | |
| Operating cycle | 391d | 448d | 478d | 456d | 374d | |
| Cash conversion cycle | -747d | -68d | -501d | -356d | -104d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years